摘要
目的研究SET结构域分支型1(SET domain bifurcated 1,SETDB1)在人卵巢癌中的表达情况以及对患者预后的影响。方法收集2010年1月~2012年12月间于笔者医院妇产科行手术切除的卵巢癌及对应癌旁组织共44例,运用qRT-PCR技术检测SETDB1 mRNA在卵巢癌及对应癌旁组织中的表达水平,免疫组化染色检测SETDB1蛋白的表达情况,通过卡方检验分析SETDB1蛋白表达与患者临床病理资料间的相关性,采用Kaplan-Meier生存曲线分析SETDB1蛋白表达水平对患者3年生存预后的影响。结果卵巢癌组织中SETDB1显著高表达(P<0.05);卵巢癌组织SETDB1蛋白阳性表达与淋巴结转移(P<0.05)及较晚的FIGO分期(Ⅲ+Ⅳ,P<0.05)具有显著的相关性;与SETDB1蛋白表达阴性患者相比,SETDB1蛋白阳性表达的患者3年总生存率及无病生存率均显著降低(P<0.05)。结论卵巢癌中SETDB1表达水平异常升高并与患者不良预后密切相关,SETDB1对卵巢癌患者可能具有一定的预后评价作用。
Objective To investigate the expression and clinical significance of SETDB1 in human ovarian carcinoma. Methods 44 ovarian carcinoma tissues and matched tumor- adjacent tissues were collected from January, 2010 to December, 2012. The mRNA expression of SETDB1 was detected by qRT- PCR, and the protein expression of SETDB1 was detected by immunohistochemistry. The correlation between SETDB1 and clinic pathological features was analyzed by chi - square test, and the Kaplan - Meier survival curves were drawn to describe the prognostic effects of SETDB1 expression. Results The expression of SETDB1 was up - regulated in ovarian carcinoma tissues compared to those matched tumor - adjacent tissues（ P 〈 0.05 ）. Positive expression of SETDB1 was associated with lymphatic metastasis （ P 〈 0.05 ） and advanced FIGO stage （ Ⅲ ＋ Ⅳ, P 〈 0.05 ）. Both the 3 - year overall survival rate and tumor - free survival rate were lower in SETDBI positive expression group than SETDB1 negative expression group （P 〈 0.05）. Conclusion Positive expression of SETDB1 in human ovarian carcinoma is related to the poor prognosis. SETDB1 has a potential to predict the prognosis for ovarian carcinoma patients.
出处
《医学研究杂志》
2017年第3期145-148,152,共5页
Journal of Medical Research
关键词
SETDB1
卵巢癌
表达
临床意义
SETDB1
Ovarian carcinoma
Expression
Clinical significance
